Hansjochen Wilke
German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer.
Overview
Hansjochen Wilke is a gastrointestinal oncologist at Kliniken Essen-Mitte. He was first author of the 2014 Lancet Oncology report of RAINBOW, which showed that adding the VEGFR2 antibody ramucirumab to paclitaxel lengthened overall survival compared with paclitaxel alone in advanced gastric or gastro-oesophageal junction adenocarcinoma after first-line therapy.
Similar pages
not linked directly; found by shared links- PersonPeter Thuss-Patience
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonManish A. Shah
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonHitoshi Katai
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonHyung-Ho Kim
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonSalah-Eddin Al-Batran
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- PersonZev A. Wainberg
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
- TrialRAINBOW
Shares RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer, PD-L1-high gastric cancer, Gastric & gastro-oesophageal junction cancer.
- TrialATTRACTION-2
Shares PD-L1-high gastric cancer, Gastric & gastro-oesophageal junction cancer.